World CDx 2026 has ended. This guide stays up as the record of who was there. Next: World CDx 2027, Aug 30 – Sep 2, 2027 in Boston
Biomarker discovery and translation at World CDx 2026
Oct 5–8, 2026 Boston, MA ~900 attendees Website
61 organizations at World CDx 2026 present work in biomarker discovery & translation: 35 technology and service providers, 22 drug developers and 4 academic, government and non-profit bodies. Between them they bring 79 presentations to the program. Most represented: Johnson & Johnson Innovative Medicine, Merck and Thermo Fisher Scientific. As of Oct 8, 2026.
Format
Top represented
Showing 1–10 of 61 organizations
| Organization | World CDx 2026 Attendance |
|---|---|
Johnson & Johnson Innovative Medicine New Brunswick, NJ | |
Pharmaceutical business of Johnson & Johnson, formerly Janssen, with medicines in oncology, immunology and neuroscience. | Talk Tue Oct 6 11:10am From Strategic Partnering to Orchestrated Partnering: Navigating the Next Era of Precision Medicine Drug–diagnostic commercialization & access Panel Tue Oct 6 6:10pm Strengthening Tumor‑Informed MRD Assays with Standardized Analytical Validation to Ensure Reliable Detection & Confident Clinical Interpretation Liquid biopsy & MRDClinical & companion diagnostic development Chair Wed Oct 7 11:19am Stream chair Talk Wed Oct 7 12:40pm MRD in IBD? Building a Precision Medicine Consortium for Deeper Endpoints in IBD Biomarker discovery & translation Talk Wed Oct 7 2:40pm If You Build It, Will They Come? Drug–diagnostic commercialization & access Panel Wed Oct 7 5:00pm Beyond the Contract: Inside a Pharma–CDx Partnership Clinical & companion diagnostic developmentDrug–diagnostic commercialization & access Talk Thu Oct 8 8:10am Expanding Access to Precision Cancer Care with the Precision Cancer Consortium CGP Implementation Guide Drug–diagnostic commercialization & accessClinical & companion diagnostic development Panel Thu Oct 8 9:00am Mobilizing Precision Cancer Care Through the Precision Cancer Consortium to Standardize Testing Pathways & Reduce Access Barriers Drug–diagnostic commercialization & access Panel Thu Oct 8 2:00pm Fit-for-Purpose CDx Strategies: Matching Testing Approaches to Development & Patient Access Needs Clinical & companion diagnostic developmentDrug–diagnostic commercialization & access |
Merck Rahway, NJ | |
US pharmaceutical company, known as MSD outside the US and Canada, with oncology medicines including pembrolizumab. | Panel Tue Oct 6 12:30pm Companion Diagnostics from Biomarker Discovery to Global Launch: Building Better Partnerships Across Science, Regulation, & Commercialization Clinical & companion diagnostic developmentDrug–diagnostic commercialization & access Talk Tue Oct 6 2:30pm Integrating Science & Strategy to Advance Companion Diagnostic Development for Optimal Patient Treatment Clinical & companion diagnostic development Panel Wed Oct 7 12:50pm Transforming Patient Enrolment & Monitoring Through Innovation in Liquid Biopsy Analytes, Detection Sensitivity & Data Interpretation Liquid biopsy & MRD Panel Wed Oct 7 3:10pm Advancing Regulatory Frameworks & Standards for Compliant Digital Pathology Co-Development Digital pathology & spatial biomarkersClinical & companion diagnostic development Talk Thu Oct 8 12:20pm A Single-Cell Platform for Linking CRISPR-Edited Variants to Transcriptional Outcomes Biomarker discovery & translation Talk Thu Oct 8 12:20pm Drug Diagnostic Co-Development: Overlooked Challenges & Mitigations Clinical & companion diagnostic development |
Thermo Fisher Scientific Waltham, MA | ◇Expertise Partner |
Supplies instruments, reagents and services for translational research and companion diagnostic development through brands including Applied Biosystems, Invitrogen and Ion Torrent. | Panel Wed Oct 7 5:00pm Beyond the Contract: Inside a Pharma–CDx Partnership Clinical & companion diagnostic developmentDrug–diagnostic commercialization & access |
GSK London, UK | |
Global biopharmaceutical company developing vaccines and specialty medicines in infectious disease, HIV, respiratory, immunology and oncology. | Panel Tue Oct 6 6:10pm Strengthening Tumor‑Informed MRD Assays with Standardized Analytical Validation to Ensure Reliable Detection & Confident Clinical Interpretation Liquid biopsy & MRDClinical & companion diagnostic development Panel Wed Oct 7 9:00am Applying AI & Advanced Data Analytics to Transform Biomarker Discovery & Clinical Trial Strategy for Improved Precision Medicine Programs Multimodal & AI-enabled precision medicineBiomarker discovery & translation Panel Wed Oct 7 12:10pm Building the Clinical & Commercial Ecosystem for AI-Enabled Precision Pathology Digital pathology & spatial biomarkersDrug–diagnostic commercialization & access Talk Thu Oct 8 9:50am When a Drug Program Expects Multiple Global Dx Partners: Considerations for Master CDx Agreements Clinical & companion diagnostic developmentDrug–diagnostic commercialization & access |
AbbVie North Chicago, IL | |
Global pharmaceutical company with medicines in immunology, oncology, neuroscience and eye care, including antibody-drug conjugates for cancer. | Panel Tue Oct 6 2:00pm Single-Cell Becomes a Reality: The Next Generation of Therapy Selection Biomarkers Biomarker discovery & translation Talk Wed Oct 7 11:50am Strategic Considerations for Global Precision Medicine ADC Biomarker Launches Drug–diagnostic commercialization & accessClinical & companion diagnostic development Talk Wed Oct 7 2:10pm From Assay to Asset: How End‑to‑End Companion Diagnostic Partnerships Deliver Strategic Platform Selection, Clinical Development Alignment, & Reliable Execution Clinical & companion diagnostic development |
AstraZeneca Cambridge, UK | |
Global pharmaceutical company with a large oncology portfolio, including targeted therapies and antibody-drug conjugates that rely on biomarker testing. | Talk Tue Oct 6 8:15am Enabling Access to Novel Computational Biomarkers: From Innovation to Impact Multimodal & AI-enabled precision medicineDrug–diagnostic commercialization & access Talk Wed Oct 7 11:50am Combining Foundation & Mathematical Models for Biomarker Discovery Multimodal & AI-enabled precision medicineBiomarker discovery & translation Panel Wed Oct 7 3:10pm Realizing the Promise, Gaps & Platform Innovation for Precision Medicine at Scale from Global Technology Leaders Multimodal & AI-enabled precision medicine Panel Thu Oct 8 9:00am Mobilizing Precision Cancer Care Through the Precision Cancer Consortium to Standardize Testing Pathways & Reduce Access Barriers Drug–diagnostic commercialization & access |
Foundation Medicine Boston, MA | ◇Expertise Partner |
Comprehensive genomic profiling company offering tissue and blood cancer tests and developing companion diagnostics with drug developers. | Talk Tue Oct 6 11:30am A Dual Tissue & Liquid Biopsy Strategy: The TEPMETKO® Companion Diagnostic Journey Clinical & companion diagnostic developmentLiquid biopsy & MRD Panel Tue Oct 6 2:00pm Single-Cell Becomes a Reality: The Next Generation of Therapy Selection Biomarkers Biomarker discovery & translation |
CellCarta Montreal, Canada | ◇Program Partner |
Specialty laboratory CRO offering immunology, histopathology, proteomics and genomics testing and sample management for biomarker work in global clinical trials. | Chair Tue Oct 6 2:00pm Chair’s Opening Afternoon Remarks Panel Wed Oct 7 11:20am Beyond the Slide: Tissue AI as the Anchor for Multimodal Biomarker Discovery & Global Deployment Digital pathology & spatial biomarkersMultimodal & AI-enabled precision medicine Talk Wed Oct 7 12:10pm The CDx Model Needs to Change – What China Taught Us About Breaking Silos, Moving Faster, & Going Global Clinical & companion diagnostic developmentDrug–diagnostic commercialization & access Talk Thu Oct 8 11:00am Can AI Predict ADC Response? Multimodal & AI-enabled precision medicineBiomarker discovery & translation |
Gilead Sciences Foster City, CA | |
Biopharmaceutical company with marketed medicines in HIV, liver disease, oncology and inflammation, including antibody-drug conjugates and CAR T therapies. | Panel Wed Oct 7 11:20am Beyond the Slide: Tissue AI as the Anchor for Multimodal Biomarker Discovery & Global Deployment Digital pathology & spatial biomarkersMultimodal & AI-enabled precision medicine Panel Wed Oct 7 2:10pm Beyond IHC Scoring: Unlocking Next-Generation Clinical Biomarkers through AI-Powered Computational Pathology Digital pathology & spatial biomarkersMultimodal & AI-enabled precision medicine Talk Wed Oct 7 2:40pm Promise & Pitfalls of Tumor Target Quantification in Antibody-Drug Conjugate & Immune Cell Engager Drug Development Biomarker discovery & translationDigital pathology & spatial biomarkers |
Beacon Scientific Consulting Cambridge, UK | ◇Meeting Partner |
Cambridge consultancy, now named Beacon Precision Medicine Partners, advising drug developers on biomarkers, companion diagnostics, regulatory strategy, market access and launch planning. | Panel Wed Oct 7 3:10pm Navigating Biomarker Complexity as a Biotech to Build Smarter Precision Oncology Strategies that Maximize Clinical & Commercial Impact Biomarker discovery & translationDrug–diagnostic commercialization & access Chair Thu Oct 8 1:35pm Chair’s Opening Afternoon Remarks |
Instantly find 20 buyers in biomarker discovery & translation
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse World CDx 2026 by
Organization type
Topic
Everyone
Not affiliated with or endorsed by World CDx or its organizers. Submit a correction